anti-BCMA-CAR-T

Phase 2Cell therapy

IInstitute of Hematology & Blood Diseases Hospital, China

anti-BCMA-CAR-T is one of 103 biologic programs targeting Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentRecruiting

Plasma Cell LeukemiaActive, not recruiting

Multiple MyelomaRecruiting

CAR T Cell TherapyRecruiting

TreatmentPhase 2

Recruiting

Plasma Cell LeukemiaPhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Recruiting

CAR T Cell TherapyPhase 2

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

anti-BCMA-CAR-T

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 2

1 2

Biltricide

Bayer

Preclinical

4 3

Dexilant

Takeda

Preclinical

2 4

Alfenta

Jazz Pharmaceuticals

Preclinical

1 5

Niclocide

Bayer

Preclinical

1 6

Minipress

Pfizer

Preclinical

1 7

Valium

Akero Therapeutics

Preclinical

2 8

Norpramin

VValidus Pharmaceuticals

Preclinical

1 9

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 10

Intuniv

PPromius Pharma, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Treatment

NCT05850286

Phase 2Active, not recruiting

Plasma Cell Leukemia

NCT05870917

Q1 2028

Phase 2Active, not recruiting

Multiple Myeloma

NCT05860036

Q2 2028

Phase 2Recruiting

CAR T Cell Therapy

NCT05846737

Q3 2028

Phase 2Recruiting

Plasma Cell Leukemia

NCT05979363

Clinical

Trials by Indication[1]

Multiple Myeloma5 trials

Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04637269·16 enrolled

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05860036·40 enrolled

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06793449·80 enrolled

Show 2 more trials

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04706936·25 enrolled

BCMA CAR-T for Dynamic High-risk Multiple Myeloma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06880393·40 enrolled

Plasma Cell Leukemia2 trials

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05979363·20 enrolled

A Prospective, Single-center, Phase II Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Newly Diagosed Primary Plasma Cell Leukemia

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05870917·20 enrolled

CAR T Cell Therapy1 trial

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05846737·20 enrolled

Treatment1 trial

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05850286·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for anti-BCMA-CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-BCMA-CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-BCMA-CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

anti-BCMA-CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q2 2028

Q3 2028

Trials by Indication[1]

Multiple Myeloma5 trials

Plasma Cell Leukemia2 trials

CAR T Cell Therapy1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News